Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433992 · ClinicalTrials.gov registry record
Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 56
- Enrollment target
NCT00433992: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00433992 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00433992 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to observe the effects of certain anti-HIV medications on mitochondrial activity and fat cell death. This study will enroll participants from another study, ACTG A5202, who are on treatment regimens that do not include zidovudine, stavudine, or other thymidine-containing anti-HIV medications.
Primary Outcome
mtDNA content in adipose tissue was measured by quantitative real-time polymerase chain-reaction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-12 |
What the finished NCT00433992 record still lists
NCT00433992 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00433992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00433992 about?
NCT00433992 is a clinical study titled "Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications". The purpose of this study is to observe the effects of certain anti-HIV medications on mitochondrial activity and fat cell death. This study will enroll participants from another study, ACTG A5202, who are on treatment regimens that do not include zidovudine, stavudine, or other thymidine-containing...
What is the current status of trial NCT00433992?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2006-04. Estimated completion is 2009-12.
Who is sponsoring clinical trial NCT00433992?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia